Monte Rosa Therapeutics Inc

GLUE

15.380USD

-0.290-1.85%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Monte Rosa Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

42 / 391

Overall Ranking

142 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Monte Rosa Therapeutics Inc Highlights

StrengthsRisks

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Undervalued

The company’s latest PE is -33.08, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 70.11M shares, increasing 1.55% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.25M shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

30.167

Target Price

+92.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Monte Rosa Therapeutics Inc is 6.81, ranking 191 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.78M, representing a year-over-year decrease of 95.41%, while its net profit experienced a year-over-year decrease of 443.34%.

Score

Industry at a Glance

Previous score

6.81

Change

0



Financials

7.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

3.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Monte Rosa Therapeutics Inc is 7.26, ranking 139 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -33.08, which is -340.69% below the recent high of 79.61 and -4.42% above the recent low of -34.54.

Score

Industry at a Glance

Previous score

7.26

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 42/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Monte Rosa Therapeutics Inc is 8.67, ranking 72 out of 391 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 20.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Monte Rosa Therapeutics Inc is 7.12, ranking 79 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 18.06 and the support level at 13.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.24

Change

-0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Monte Rosa Therapeutics Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.98%, representing a quarter-over-quarter decrease of 4.93%. The largest institutional shareholder is PRFDX, holding a total of 5.02M shares, representing 6.28% of shares outstanding, with 41.12% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

7.69M

--

Dimension Management, L.P.

4.76M

--

T. Rowe Price Associates, Inc.

Star Investors

4.54M

-27.09%

TCG Crossover Management, LLC

4.43M

--

Baker Bros. Advisors LP

4.92M

--

BVF Partners L.P.

5.66M

--

BlackRock Institutional Trust Company, N.A.

3.30M

-1.64%

Suvretta Capital Management, LLC

3.36M

--

Versant Ventures

4.91M

-13.18%

The Vanguard Group, Inc.

Star Investors

2.99M

-4.83%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Monte Rosa Therapeutics Inc is 3.20, ranking 161 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.66. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Monte Rosa Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Monte Rosa Therapeutics Inc

GLUE

7.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment